Related Experiment Video
Updated: Sep 3, 2025
06:03
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
6.7K
Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study
Jiayi Zhang1, Gang Wu2, Hailong Zhu2
1Department of Ultrasonography, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Frontiers in Oncology
|July 25, 2022
Summary
Carnitine levels show a complex link to breast cancer risk. Higher malonylcarnitine (C3DC), decenoylcarnitine (C10:1), and decadienoylcarnitine (C10:2) may protect against breast cancer, while butyrylcarnitine (C4) may increase risk.
Area of Science:
- Metabolomics
- Cancer Epidemiology
- Biochemistry
Background:
- Research on carnitine and breast cancer is limited.
- Carnitine plays a role in fatty acid metabolism.
Purpose of the Study:
- To investigate the association between various carnitine compounds and breast cancer risk.
- To identify potential biomarkers for breast cancer risk assessment.
Main Methods:
- A retrospective case-control study involving 991 breast cancer cases and 991 controls.
- Targeted metabolomics was used to quantify 16 whole blood carnitine compounds.
- Statistical analysis adjusted for relevant covariates.
Main Results:
- Increased levels of malonylcarnitine (C3DC), decenoylcarnitine (C10:1), and decadienoylcarnitine (C10:2) were associated with decreased odds of breast cancer.
- Elevated butyrylcarnitine (C4) levels were linked to increased odds of breast cancer.
- No significant associations were found for other measured carnitine compounds.
Conclusions:
- Specific carnitine compounds, including C3DC, C10:1, and C10:2, may act as protective factors against breast cancer.
- Elevated C4 levels may represent a risk factor for breast cancer development.
- Further research is warranted to elucidate the precise roles of carnitine metabolism in breast carcinogenesis.
